Dietary Intake of Polyunsaturated Fatty Acids and Pain in Spite of Inflammatory Control Among Methotrexate-Treated Early Rheumatoid Arthritis Patients

Arthritis Care Res (Hoboken). 2018 Feb;70(2):205-212. doi: 10.1002/acr.23245.

Abstract

Objective: To investigate potential associations between dietary intake of polyunsaturated fatty acids (FAs) and pain patterns in early rheumatoid arthritis (RA) patients after 3 months of methotrexate (MTX) treatment.

Methods: We included 591 early RA patients with MTX monotherapy from a population-based prospective case-control study, the Epidemiological Investigation of Rheumatoid Arthritis. Dietary data on polyunsaturated FAs (food frequency questionnaires) were linked with data on unacceptable pain (visual analog scale [VAS] >40 mm), noninflammatory/refractory pain (VAS >40 mm and C-reactive protein [CRP] level <10 mg/liter), and inflammatory pain (VAS >40 mm and CRP level >10 mg/liter) after 3 months. Statistical analysis included logistic regression.

Results: After 3 months of MTX treatment, 125 patients (21.2%) had unacceptable pain, of which 92 patients had refractory pain, and 33 patients had inflammatory pain. Omega-3 FA intake was inversely associated with unacceptable pain and refractory pain (odds ratio [OR] 0.57 [95% confidence interval (95% CI) 0.35-0.95] and OR 0.47 [95% CI 0.26-0.84], respectively). The omega-6:omega-3 FA ratio, but not omega-6 FA alone, was directly associated with unacceptable pain and refractory pain (OR 1.70 [95% CI 1.03-2.82] and OR 2.33 [95% CI 1.28-4.24], respectively). Furthermore, polyunsaturated FAs were not associated with either inflammatory pain or CRP level and erythrocyte sedimentation rate at followup. Omega-3 FA supplementation was not associated with any pain patterns.

Conclusion: Omega-3 FA was inversely associated with, and the omega-6:omega-3 FA ratio was directly associated with, unacceptable and refractory pain, but not with inflammatory pain or systemic inflammation. The inverse association between omega-3 FA and refractory pain may have a role in pain suppression in RA.

MeSH terms

  • Adult
  • Aged
  • Antirheumatic Agents / adverse effects
  • Antirheumatic Agents / therapeutic use*
  • Arthralgia / blood
  • Arthralgia / diagnosis
  • Arthralgia / drug therapy*
  • Arthralgia / physiopathology
  • Arthritis, Rheumatoid / blood
  • Arthritis, Rheumatoid / diagnosis
  • Arthritis, Rheumatoid / drug therapy*
  • Arthritis, Rheumatoid / physiopathology
  • Biomarkers / blood
  • Blood Sedimentation
  • C-Reactive Protein / metabolism
  • Case-Control Studies
  • Diet* / adverse effects
  • Fatty Acids, Omega-3 / administration & dosage*
  • Fatty Acids, Omega-3 / adverse effects
  • Fatty Acids, Omega-6 / administration & dosage*
  • Fatty Acids, Omega-6 / adverse effects
  • Female
  • Humans
  • Inflammation Mediators / blood
  • Male
  • Methotrexate / adverse effects
  • Methotrexate / therapeutic use*
  • Middle Aged
  • Pain Measurement
  • Pain, Intractable / blood
  • Pain, Intractable / diagnosis
  • Pain, Intractable / drug therapy*
  • Pain, Intractable / physiopathology
  • Prospective Studies
  • Protective Factors
  • Risk Factors
  • Time Factors
  • Treatment Outcome

Substances

  • Antirheumatic Agents
  • Biomarkers
  • Fatty Acids, Omega-3
  • Fatty Acids, Omega-6
  • Inflammation Mediators
  • C-Reactive Protein
  • Methotrexate